Диссертация (1139439), страница 42
Текст из файла (страница 42)
Br J Haematol.2005;128:738. [PMID: 15755276]342. Viale PH, Lin A. Exposed bone in oral cavities. Clin J Oncol Nurs. 2005;9: 3557. [PMID: 15973847]343. Vincenzi B, Santini D, Rocci L, et al: Bisphosphonates: New antiangiogenicmolecules in cancer treatment? Ann Oncol 14:806-807, 2003344. Vitte C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secretean inhibitor of osteoclast-mediated resorption. Endocrinol 1996;137:2324-2333345. von Schewelov T, Carlsson A, Dahlberg L.
Cross-linked N-telopeptide of type Icollagen (NTx) in urine as a predictor of periprosthetic osteolysis. J Orthop Res 2006;24(7):1342–8346. von Wowern N, Hjdrting-Hansen E, Edeling CJ. Bone scintigraphy of benign jawlesions. Int J Oral Surg 1978;7:528-33347. Vudiniabola S, Pirone C, Williamson J, Goss AN. Hyperbaric oxygen in thetherapeutic management of osteoradionecrosis of the facial bones. Int J Oral MaxillofacSurg 2000;29:435-438.331348. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associatedwithcancerchemotherapy.JOralMaxillofacSurg2003;61:1104–1107.[PubMed:12966490])349.
Wannfors K. Vascular changes after experimentally induced inflammation in themandible. Int J Oral Maxillofac Surg 1989;18:79-82350. Watts NB. Bisphosphonate treatment for osteoporosis. In: Avioli LV, ed. TheOsteoporotic Syndrome. San Diego, CA: Academic Press, 2000, pp 121–132.351. Watts, N.B., Marciani R.D. Osteonecrosis of the Jaw // Southern Medical Journal.101(2):160-165, February 2008. doi: 10.1097/SMJ.0b013e31816127d9352. Whyte MP,Wenkert D,ClementsKL,McAlisterWH,Mumm S.Bisphosphonate-induced osteopetrosis.
N Engl J Med 2003;349:457-63.353. Woo S. -B, Hellstein J.W., Kalmar J.R. Systematic Review: Bisphosphonates andOsteonecrosis of the Jaws // Ann Intern Med. 2006;144:753-761.354. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of thebisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-1061355.
Wood RE, Nortjt CJ, Grotepass F, Schmidt S, Harris AMP. Periostitis ossificansversus Garrb’s osteomyelitis. Part I. What did Garrb really say? ORAL SURG ORALMED ORAL PATHOL l988;65:173-I.356. Xing L, Boyce BF. Regulation of apoptosis in osteoclasts and osteoblastic cells.Biochem Biophys Res Commun 2005;328:709-20.357. Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S. Osteonecrosis ofthe jaw induced by orally administered bisphosphonates: incidence, clinical features,predisposing factors and treatment outcome.
Osteoporos Int 2007;18(10):1363-1370.358. Yeo AC, Lye KW, Poon CY. Bisphosphonate-related osteonecrosis of the jaws.Singapore Dent J. 2005;27:36-40. [PMID: 16438267]359. Zarychanski R, Elphee E, Walton P, Johnston J. Osteonecrosis of the jawassociated with pamidronate therapy.
Am J Hematol. 2006;81:73-5. [PMID: 16369966]360. Zavras AI, Zhu S. Bisphosphonate are associated with increased risk for jawsurgery in medical claims data; is it osteonecrosis? J Oral Maxillofac Surg 64:917, 2006332361. Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, Krikelis D,Terpos E 2006 Incidence, risk factors and management of osteonecrosis of the jaw inpatients with multiple myeloma: A single-centre experience in 303 patients.
Br JHaematol 134:620–623..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
